Can Gene Therapy Help Treat Usher Syndrome Patients with Retinitis Pigmentosa?
March 12, 2012
Last week, the Foundation Fighting Blindness and Oxford BioMedica announced that the first Usher Syndrome patient is about to be treated at Casey Eye Institute (OHSU) with Oxford’s UshStat gene therapy treatment.
The trial is aimed at patients with Usher Syndrome Type 1B, a form or retinitis pigmentosa that leads to blindness and hearing loss.
There is currently no treatment for this disease.
Based on laboratory pre-clinical studies, the researchers believe that a single UshStat treatment may last for several years, and perhaps for a lifetime.
In addition, Oxford BioMedica issued an update on all of its ophthalmic gene therapy programs, as part of its year-end report.
To read the full article, please follow this link.
You might also enjoy...
- Gene Therapy Trial for Retinitis Pigmentosa Based on Usher’s Syndrome To Begin
- 2nd Clinical Site for Gene Therapy Trial for Usher Syndrome
- Will 2012 be the Year for Gene Therapy in Ophthalmology?
- Current Status of Stem Cells and Gene Therapy in Ophthalmology
- Early Positive Results in Ongoing Gene Therapy Trials for Wet AMD and Stargardt’s
Jump down to form below to submit your own comments